AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32503620
Drug: Lopinavir/Ritonavir (Kaletra)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/Ritonavir (Kaletra) + Colchicine 1.5 mg loading then 0.5 mg twice daily orally
Trial: 33259999
Drug: Transvaginal high-intensity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transvaginal high-intensity focused ultrasound (vHIFU) therapy
Trial: 33877743
Drug: Doxycycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (100 mg daily for 7 days)
Trial: 33877743
Drug: Roxithromycin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxithromycin (300 mg daily for 7 days)
Trial: 33877743
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no antibiotics given)
Trial: 32539288
Drug: 33% of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 33% of daily TAF (25 mg)/FTC (200 mg)
Trial: 32539288
Drug: 67% of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 67% of daily TAF (25 mg)/FTC (200 mg)
Trial: 32539288
Drug: 100% of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100% of daily TAF (25 mg)/FTC (200 mg)
Trial: 32068049
Drug: 5% sofpironium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% sofpironium bromide gel
Trial: 32068049
Drug: 10% sofpironium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% sofpironium bromide gel
Trial: 32068049
Drug: 15% sofpironium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15% sofpironium bromide gel
Trial: 32332634
Drug: Herbal medicine
RxNorm normalized name: Herbal medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal medicine foot bath decoction (FBD) with ordinary dressing changes
Trial: 36306329
Drug: NETfacts health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NETfacts health system (integrated model of Narrative Exposure Therapy and community-based intervention)
Trial: 34930153
Drug: Astra‐Zeneca ChAdOx1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astra‐Zeneca ChAdOx1 vaccine
Trial: 39325828
Drug: Pfizer BNT162b2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pfizer BNT162b2 vaccine
Trial: 35318632
Drug: Multimedia insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multimedia insulin pen-injector health education intervention
Trial: 32741502
Drug: Oxytocin 40-IU
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin 40-IU administered intranasally prior to each of six weekly motivational interviewing group therapy (MIGT) sessions
Trial: 32741502
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered intranasally prior to each of six weekly motivational interviewing group therapy (MIGT) sessions
Trial: 34101252
Drug: Intensive nutrition
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive nutrition treatment (INT) with protein intake of 1.70 ± 0.21 g/kg/d
Trial: 34101252
Drug: Standard nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard nutrition treatment (SNT) with protein intake of 1.06 ± 0.21 g/kg/d
Trial: 34872511
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (HCQ) 400 mg twice a day for the first day followed by 200 mg twice daily for the next 4 days plus standard of care (SOC) treatment
Trial: 33155057
Drug: Green light-emitting
RxNorm normalized name: light green SF yellowish
DrugBank: Light green SF yellowish (DB11183)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green light-emitting diodes (GLED) for 1 to 2 hours daily for 10 weeks
Trial: 36395875
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus ticagrelor (AT group)
Trial: 36395875
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus clopidogrel (AC group)
Trial: 36405056
Drug: Date palm
RxNorm normalized name: date palm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Date palm pollen (DPP) supplementation (300 mg per day for 35 days)
Trial: 32966810
Drug: Surufatinib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surufatinib (300 mg, orally once per day)
Trial: 33205673
Drug: 6-mercaptopurine (6MP)
RxNorm normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6-mercaptopurine (6MP) at a fixed dose of 25 mg/m2/day
Trial: 33205673
Drug: 6-mercaptopurine (6MP)
RxNorm normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6-mercaptopurine (6MP) escalation (up to 50 or 75 mg/m2/day)
Trial: 33205673
Drug: High-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate (HD-MTX), asparaginase, and vincristine
Trial: 32507128
Drug: Oxycodone PR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone PR tablet with naltrexone (T+)
Trial: 32507128
Drug: Oxycodone PR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone PR tablet without naltrexone (T)
Trial: 32507128
Drug: Oxygesic PR
RxNorm normalized name: acetaminophen / hydrocodone bitartrate Oral Capsule [Polygesic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygesic PR tablet with naltrexone (R+)
Trial: 32507128
Drug: Oxygesic PR
RxNorm normalized name: acetaminophen / hydrocodone bitartrate Oral Capsule [Polygesic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygesic PR tablet without naltrexone (R)
Trial: 616173046
Drug: Digoxin (D,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin (D, 0.25 mg)
Trial: 616173046
Drug: Ivabradine (I,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivabradine (I, 15 mg)
Trial: 616173046
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (non-receiving both drugs)
Trial: 32740086
Drug: Corticotropin-releasing factor
RxNorm normalized name: corticotropin-releasing factor
DrugBank: Corticorelin ovine triflutate (DB09067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticotropin-releasing factor (CRF) 100 μg
Trial: 32740086
Drug: 5-mL saline
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-mL saline solution (placebo)
Trial: 32682929
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of vitamin C daily for 30 days
Trial: 32682929
Drug: 1.2 g
RxNorm normalized name: Humidifier 1.2 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 g of NAC daily for 30 days
Trial: 32682929
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of vitamin C
Trial: 32682929
Drug: 1.2 g
RxNorm normalized name: Humidifier 1.2 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 g of NAC
Trial: 32682929
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of vitamin C and 1.2 g of NAC
Trial: 35413719
Drug: DHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA supplementation (1.2 g daily)
Trial: 35906473
Drug: Inulin supplementation
RxNorm normalized name: Inulin
DrugBank: Inulin (DB00638)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Inulin supplementation (13 g of extracted inulin powder from Thai Jerusalem artichoke)
Trial: 32631414
Drug: Individualized PEEP
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized PEEP (iPEEP) determined by Cstat-directed PEEP titration
Trial: 38976448
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg once daily for 8 weeks
Trial: 34655014
Drug: High-volume group
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-volume group received 3600 mL of lactated Ringer's solution (LRS) in 24 hours starting 2 hours before the ERCP.
Trial: 33077680
Drug: Intravenous t-PA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous t-PA
Trial: 32347139
Drug: Standard FEC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard FEC chemotherapy (600/60/600 mg/m2)
Trial: 32347139
Drug: Chemotherapy-induced leukopenia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy-induced leukopenia
Trial: 35025757
Drug: 0.2% Hyaluronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% Hyaluronic Acid cream
Trial: 35025757
Drug: Neutral comparator
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutral comparator cream (identical cream without HA)
Trial: 35363058
Drug: Mindful Walking
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mindful Walking Program (MWP) - eight weekly sessions
Trial: 32052516
Drug: Dapagliflozin (DAPA)
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin (DAPA) 10 mg + Saxagliptin (SAXA) 5 mg
Trial: 32052516
Drug: Glimepiride (GLIM)
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glimepiride (GLIM) 1-6 mg (titrated)
Trial: 35877601
Drug: Bedaquiline (TB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedaquiline (TB drug)
Trial: 35877601
Drug: Pretomanid (TB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pretomanid (TB drug)
Trial: 35877601
Drug: Dolutegravir (HIV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir (HIV drug)
Trial: 35877601
Drug: Doravirine (HIV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doravirine (HIV drug)
Trial: 35877601
Drug: Sofosbuvir (HCV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir (HCV drug)
Trial: 35877601
Drug: Glecaprevir/pibrentasvir (HCV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glecaprevir/pibrentasvir (HCV drug)
Trial: 35877601
Drug: TB drugs
RxNorm normalized name: dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TB drugs (Bedaquiline and Pretomanid)
Trial: 33978188
Drug: Citicoline (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citicoline (500 mg/d) for 12 weeks
Trial: 35634651
Drug: Generic measures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic measures of discrimination (e.g., social distance scales)
Trial: 34165010
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with 25OHD <20 ng/ml
Trial: 34165010
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with 25OHD <10 ng/ml
Trial: 34107861
Drug: Gui‐fu‐di‐huang‐wan (GFDHW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gui‐fu‐di‐huang‐wan (GFDHW) treatment and lifestyle intervention
Trial: 34107861
Drug: GFDHW treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GFDHW treatment and lifestyle intervention
Trial: 34360425
Drug: Beta-Alanine (6.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-Alanine (6.4 g)
Trial: 36205739
Drug: TAC-302 200
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TAC-302 200 mg twice daily for 12 weeks
Trial: 34978388
Drug: Generic roxatidine
RxNorm normalized name: ROXATIDINE
DrugBank: Roxatidine acetate (DB08806)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic roxatidine acetate hydrochloride (RAH) sustained-release capsule, 75 mg
Trial: 34978388
Drug: Commercial capsule
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercial capsule (ALTAT)
Trial: 36506468
Drug: Early-start group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early-start group (aspirin 100 mg daily starting 3 days after operation)
Trial: 36506468
Drug: Normal-start group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal-start group (no antithrombotic therapy until 30 days after operation)
Trial: 32606057
Drug: Vibration treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vibration treatment with HMB supplementation
Trial: 33326694
Drug: teriparatide (20 μg/day,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: teriparatide (20 μg/day, daily subcutaneous injection for 6 months)
Trial: 33326694
Drug: combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combined treatment of WJ‐MSCs (intramedullary [4 × 107 cells] injection and intravenous [2 × 108 cells] injection after 1 week) and teriparatide (20 μg/day, daily subcutaneous injection for 6 months)
Trial: 33326694
Drug: combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combined treatment of WJ‐MSCs and teriparatide
Trial: 33766533
Drug: Postmastectomy radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postmastectomy radiotherapy (PMRT) or supraclavicular radiation therapy (SCV RT)
Trial: 32753064
Drug: Lactated Ringer's
RxNorm normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactated Ringer's solution (crystalloid group)
Trial: 34120363
Drug: Protease supplementation
RxNorm normalized name: protease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease supplementation at 500 g/ton in low protein diet (29% CP)
Trial: 34120363
Drug: Protease supplementation
RxNorm normalized name: protease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease supplementation at 250 g/ton in normal protein diet (30% CP)
Trial: 35642288
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (maintained daily activities without special physical training)
Trial: 34103345
Drug: Restarting antiplatelet
RxNorm normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Restarting antiplatelet therapy
Trial: 34039013
Drug: Apalutamide (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apalutamide (240 mg/day) plus continuous androgen deprivation therapy (ADT)
Trial: 34039013
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus continuous androgen deprivation therapy (ADT)
Trial: 34620907
Drug: Anti-adhesion agent
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-adhesion agent Collabarrier
Trial: 34620907
Drug: Placebo (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (no anti-adhesion agent)
Trial: 34887317
Drug: Albuterol/budesonide (180/160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol/budesonide (180/160 µg or 180/80 µg, two actuations of 90/80 µg or 90/40 µg)
Trial: 34887317
Drug: Albuterol (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol (180 µg, two actuations of 90 µg)
Trial: 33205741
Drug: PfSPZ Vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PfSPZ Vaccine (radiation-attenuated, 2.7 × 10^6 PfSPZ, three doses at 8-week intervals)
Trial: 33205741
Drug: PfSPZ-CVac (infectious,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PfSPZ-CVac (infectious, 1.0 × 10^5 PfSPZ, three doses at 4-week intervals)
Trial: 32341595
Drug: Rapid glucocorticoid
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid glucocorticoid tapering
Trial: 32341595
Drug: Conventional glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional glucocorticoid tapering
Trial: 34266323
Drug: Standard rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard rehabilitation treatment (control group) (n=48)
Trial: 34263971
Drug: Licogliflozin 50
RxNorm normalized name: Licogliflozin
DrugBank: Licogliflozin (DB15048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licogliflozin 50 mg TID
Trial: 33136923
Drug: Brexpiprazole (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brexpiprazole (1, 2, or 3 mg)
Trial: 33136923
Drug: Brexpiprazole (OLE,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brexpiprazole (OLE, flexible-dose 0.5-3 mg/d)
Trial: 32233639
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment with small bone window hematoma removal
Trial: 33357499
Drug: Benralizumab (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benralizumab (30 mg every 8 weeks, first three doses given 4 weeks apart)
Trial: 35294812
Drug: donidalorsen (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: donidalorsen (80 mg)
Trial: 33129289
Drug: Nano-Curcumin 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nano-Curcumin 80 mg
Trial: 33568279
Drug: Intravenous tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tranexamic acid administration at induction for hemiarthroplasty
Trial: 33568279
Drug: Intravenous tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tranexamic acid administration at induction for intramedullary nail fixation
Trial: 36356829
Drug: Standard-dose nVNS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose nVNS
Trial: 36356829
Drug: High-dose nVNS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose nVNS
Trial: 36252858
Drug: Laboratory digital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laboratory digital workflow (l‐DW)
Trial: 32282525
Drug: Postpartum pelvic
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postpartum pelvic floor physical therapy (PFPT)
Trial: 33380704
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (traditional therapy + placebo)
Trial: 35771353
Drug: BNT162b1 mRNA
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b1 mRNA vaccine (10 µg dose)
Trial: 35771353
Drug: BNT162b1 mRNA
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b1 mRNA vaccine (30 µg dose)
Trial: 35771353
Drug: BNT162b1 mRNA
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b1 mRNA vaccine (in older participants)
Trial: 35771353
Drug: BNT162b1 mRNA
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b1 mRNA vaccine
Trial: 35314431
Drug: Non-antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-antibiotic treatment options
Trial: 35314431
Drug: Postponing antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postponing antibiotic treatment by up to 3 days
Trial: 34597318
Drug: Soft occlusive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft occlusive splint therapy (OST)
Trial: 36221988
Drug: Increased fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased fluid consumption (≥2.2 L total beverage intake, with 1.9 L being water)
Trial: 34073918
Drug: BoNT‐A injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BoNT‐A injection (time between stroke onset and injection ≤90 days)
Trial: 34933568
Drug: REL-1017 25
RxNorm normalized name: (2R*,3S)-rel-1,2,3,4-butanetetroltetranitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REL-1017 25 mg/day
Trial: 34933568
Drug: REL-1017 50
RxNorm normalized name: (2R*,3S)-rel-1,2,3,4-butanetetroltetranitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REL-1017 50 mg/day
Trial: 33714847
Drug: Nelotanserin 80
RxNorm normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nelotanserin 80 mg
Trial: 33278897
Drug: Thermal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermal therapy + exercises
Trial: 33482631
Drug: Taking ≥8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taking ≥8 medications
Trial: 33482631
Drug: Cutoff of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cutoff of 5 medications
Trial: 35762448
Drug: Cloti‐Xa™ (40 mg/0.4 ml)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cloti‐Xa™ (40 mg/0.4 ml)
Trial: 33564120
Drug: Gemtuzumab ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Gemtuzumab ozogamicin (GO) combined with standard chemotherapy
Trial: 33564120
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy alone (control)
Trial: 33367742
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg Clomiphene Citrate (CC) from Day 3 to 7 and 450 IU HMG
Trial: 33367742
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg Clomiphene Citrate (CC) from Day 3 to 7 and 150 IU HMG